May 11 marked the end of the federal COVID-19 public health emergency. Locally produced online dashboards have been offline since March and even the Centers for Disease Control and Prevention ceased to produce its weekly COVID data tracker.
That doesn’t mean cases are nonexistent, though. To that end, biotech and diagnostic company Novel Microdevices is still working to fine-tune its PCR testing technology. The East Baltimore-based company’s focus on improving diagnostic capabilities is further enabled by its recent receipt of a $1.4 million Phase 1 award from the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) program. This funding will support the company’s development of its rapid point-of-care RT-PCR platform.
Andrea Pais, the founder and CEO of the East Baltimore-based medical device developer, is confident in the technology’s market case and medical intervention.
READ FULL ARTICLE HERE
